title: Multisite inhibition by phenylacetate of PC-3 cell growth.
abstract: Phenylacetate (PA) is a reversible inhibitor of tumor cell growth and an inhibitor of mevalonate pyrophosphate decarboxylase (MPD). We hypothesized that MPD inhibition should lower rates of protein accumulation and accretion of cell number in all cell lines regardless of tumorigenic status or origin of the cell lines. PA treatment inhibited growth of MCF-7, NIH-3T3, Detroit 551, UT-2, NCTC-929, COS-1 and PC-3 cell lines. NCTC-929 cells lack cadherins and Cos-1 cells are deficient in PPARalpha and PPARgamma, proteins suggested to be central to the action of PA. Oxidative metabolism was not impeded by PA treatment. One-dimensional and two-dimensional FACS analysis of BrdU incorporation failed to demonstrate a redistribution of nuclei in the cell cycle or that the rate of cells entering S phase had changed. Time-lapse photo-microscopy studies reveal a process that left condensed nuclei with little or no cytoplasm. However, negative TUNEL assay results and failure to block cell loss with z-VAD-fmk suggest this type of cell death is not typical apoptosis, but cell death is responsible for the lower rates of cell and protein accumulation. Supplementation studies with mevalonate pathway intermediates during inhibition of the mevalonate pathway of cholesterol biosynthesis by lovastatin confirmed MPD as a site of PA inhibition of growth, but in the presence of lovastatin with or without farnesyl pyrophosphate plus geranylgeranyl pyrophosphate, additive inhibition by PA revealed additional site(s). The existence of site(s) in addition to MPD suggests effective PA-based agents might be developed that would not inhibit MPD.
authors.affiliation: Sarver Heart Center, Department of Medicine, University of Arizona, Tucson, AZ 85724-5046, USA. bahlj@u.arizona.edu
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Bahl
authors.forename: Richard L
authors.initials: RL
authors.lastname: De Armond
authors.forename: Rubin
authors.initials: R
authors.lastname: Bressler
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D002522:Chlorocebus aethiops; D020287:In Situ Nick-End Labeling; D008148:Lovastatin / Q000494:pharmacology; D010648:Phenylacetates / Q000494:pharmacology*; D011106:Polyisoprenyl Phosphates / Q000037:antagonists & inhibitors; D051381:Rats; D012717:Sesquiterpenes; D013997:Time Factors
chemical_list: D000924:Anticholesteremic Agents; D000964:Antimetabolites, Antineoplastic; D010648:Phenylacetates; D011106:Polyisoprenyl Phosphates; D012717:Sesquiterpenes; C004808:farnesyl pyrophosphate; D008148:Lovastatin; D002262:Carboxy-Lyases; C022503:pyrophosphomevalonate decarboxylase; C025136:phenylacetic acid; C002963:geranylgeranyl pyrophosphate